Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production.
Cynarin
Dicaffeolyliquinic acid
Ebola virus VP35
Ebola virus inhibition
RNA binding protein inhibitor
Type I IFN antagonist
Viral immune antagonist
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
19
08
2021
revised:
16
12
2021
accepted:
17
01
2022
pubmed:
24
1
2022
medline:
3
5
2022
entrez:
23
1
2022
Statut:
ppublish
Résumé
Ebola virus (EBOV) is one of the deadliest infective agents whose lethality is linked to the ability to efficiently bypass the host's innate antiviral response. EBOV multifunctional protein VP35 plays a major role in viral replication both as polymerase cofactor and interferon (IFN) antagonist. By hiding the non-self 5'-ppp dsRNA from the cellular receptor RIG-I, VP35 prevents its activation and inhibits IFN-β production. Blocking VP35-dsRNA interaction and IFN-β suppression is a validated drug target. We screened a library of natural extracts and found that cynarin inhibits dsRNA-VP35 binding with an IC
Identifiants
pubmed: 35066016
pii: S0166-3542(22)00019-5
doi: 10.1016/j.antiviral.2022.105251
pii:
doi:
Substances chimiques
Antiviral Agents
0
Cinnamates
0
RNA, Double-Stranded
0
Viral Regulatory and Accessory Proteins
0
Interferon-beta
77238-31-4
cynarine
85D81U9JAV
Interferons
9008-11-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105251Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.